Reverse DCF
What growth does the market imply for JAGSNPHARM?
Working backwards from the current price to find the FCF growth assumption baked in.
reasonable
10.4% implied annual FCF growth
The market's growth assumption looks achievable — it is in line with or below what this company has historically delivered.
Current Price
₹197
Historical Growth
18.0%
FCF Yield
4.17%
Price / FCF
24.0x
Plain English
To justify today's price of $196.50, JAGSNPHARM.NS needs to grow its free cash flow at 10.4% per year for the next 10 years. That is 7.6% slower than its historical growth rate of 18.0%. This looks achievable — the market is not pricing in heroic assumptions. There may be genuine upside if the company executes.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Half implied | 5.2% | ₹132 | -32.7% |
| GDP rate | 10.0% | ₹191 | -3.0% |
| Implied | 10.4% | ₹197 | +0.2% |
| Historical | 18.0% | ₹352 | +79.3% |
At Historical Growth Rate
It would take 4 years for JAGSNPHARM to organically grow into today's price assuming its historical FCF growth of 18.0%.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, Monte Carlo, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.